Publications

Laboratory Safety

BOOKS:

  1. Öryggishandbók rannsóknarstofunnar [Handbook of Laboratory Safety]. 184 pages. Háskólaútgáfan, Reykjavik 2010 (link to each chapter)

REVIEW ARTICLES:

  1. Guo, S., Beleites, C., Neugebauer, U., Abalde-Cela, S., Afseth, N.K., Alsamad, F., Anand, S., Araujo-Andrade, C., Aškrabić, S., Avci, E., Baia, M., Baranska, M., Baria, E., Carvalho, L.A.E.B., Bettignies, P., Bonifacio, A., Bonnier, F., Brauchle, E.M., Byrne, H.J., Chourpa, I., Cicchi, R., Cuisinier, F., Culha, M., Dahms, M., David, C., Duponchel, L., Duraipandian, S., El-Mashtoly, S.F., Ellis, D.I., Eppe, G., Falgayrac, G., Gamulin, O., Gardner, B., Gardner, P., Gerwert, K., Giamarellos-Bourboulis, E.J., Gizurarson, S., Gnyba, M., Goodacre,R., Grysan, P., Guntinas-Lichius, O., Helgadottir, H., Grošev, V.M., Kendall, C., Kiselev, R., Kölbach, M., Krafft, C., Krishnamoorthy, C., Kubryck, P., Lendl, B., Loza-Alvarez, P., Lyng, F.M., Machill, S., Malherbe, C., Marro, M., Marques, M.P.M., Matuszyk, E., Morasso, C.F., Moreau, M., Muhamadali, H., Mussi, V., Notingher, I., Pacia, M.Z., Pavone, F.S., Penel, G., Petersen, D., Piot, O., Rau, J.V., Richter, M., Rybarczyk, M.K., Salehi, H., Schenke-Layland, K., Schlücker, S., Schosserer, M., Schütze, K., Sergo, V., Sinjab, F., Smulko, J., Sockalingum, G., Stiebing, C., Stone, N., Untereiner, v., Vanna, R., Wieland, K., Popp, J:, Bocklitz, T. Comparability of Raman Spectroscopic Configurations: A Large Scale Cross-Laboratory Study. Analytical Chemistry (in press)
  2. Sammar M, Drobnjak T, Mandala M, Gizurarson S, Huppertz B, Meiri H. Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy. Int. J. Molecular Sci. 20, 3192 (17p), 2019
  3. Schijns V, Fernández-Tejada A, Barjaktarović Ž, Bouzalas I, Brimnes J, Chernysh S, Gizurarson S, Gursel I, Jakopin Ž, Lawrenz M, Nativi C, Paul S, Pedersen GK, Rosano C, Ruiz-de-Angulo A, Slütter B, Thakur A, Christensen D, Lavelle EC. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews 296, 169-190 (22p), 2020
  4. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for CNS indication (Invited article). Brain Research Bulletin, 143, 155-170, 2018
  5. Meiri H, Osol G, Cetin I, Gizurarson S, Huppertz B. Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients with Impaired PP13 Molecule or Function. Computational and Structural Biotechnology Journal, 15, 433-446, 2017
  6. Gizurarson S: The Effect of Cilia and the Mucociliary Clearance on Successful Drug Delivery. Biol. Pharm. Bull. 38 (4), 497-506, 2015
  7. Than GN, Balogh A, Romero R, Kárpáti É, Erez O, Szilágyi A, Kovalszky I, Sammar M, Gizurarson S, Matkó J, Závodszky P, Papp Z, Meiri H. Placental protein 13 (PP13) - a placental immunoregulatory galectin protecting pregnancy. Frontiers in Immunology 5 (Article 348), 1-25, 2014  (Link)
  8. Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Human Reproduction Update 19 (4), 391-405, 2013 (Link)
  9. Björnsdóttir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 57 (9) 904-910, 2013 (Link)
  10. Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Current drug delivery 9 (6), 566-582, 2012 (Link)
  11. Gizurarson S. History of Intranasal Delivery and the Nose. Pharmaceutical Historian 41 (4), 66-72, 2011
  12. S. Gizurarson: Clinically relevant vaccine-vaccine interactions: a guide for practitioners. BioDrugs 9, 443-453, 1998 (Invited contribution)
  13. S. Gizurarson: Optimal delivery of vaccines. Clinical pharmacokinetical considerations. Clin. Pharmacokin. 30, 1-16, 1996 (Invited contribution)
  14. S. Gizurarson: The relevance of nasal physiology to the design of drug absorption studies. Advanced Drug Deliv. Rev. 11, 329-347, 1993 (Invited contribution)
  15. S. Gizurarson: In situ method to estimate local effect of nasal preparations. Scand. J. Lab. Anim. Sci. 19, 129-135, 1992
  16. S. Gizurarson & E. Bechgaard: Intranasal application of insulin to humans. Diab. Res. Clin. Pract. 12, 71-84, 1991 (link)
  17. S. Gizurarson: Animal models for intranasal drug delivery studies. Acta Pharm. Nord. 2, 105-122, 1990

ARTICLES

  1. Patlolla VGR, Holbrook WP, Gizurarson S, Kristmundsdottir Þ. Long-term stabilization of aqueous doxycycline formulations, in mucoadhesive hydrogels for treatment of oral mucosal conditions. Curr. Drug Discov. Technol. 17, 376-386, 2020
  2. Helgadóttir H, Lund SH, Gizurarson S, Metz DC, Björnsson ES. Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. J. Clin Gastroenterol. 54, 227-234 (8p), 2020
  3. Helgadottir H, Tropea T, Gizurarson S, Meiri H, Mandala M. Vasodilatation of aspirin on resistant arteries from non-gravid vs. gravid rats. Pregnancy Hypertension, 15, 141-145, 2019
    90. Drobnjak T, Jónsdóttir AM, Helgadóttir H, Runólfsdóttir MS, Meiri H, Mandalá M, Huppertz B, Gizurarson S. Placental Protein 13 (PP13) stimulates rat uterine vessels after slow subcutaneous administration. Int. J. Womens Health, 11, 213-22, 2019
  4. Patlolla VGR, Holbrook WP, Gizurarson S, Kristmundsdottir Þ. Doxycycline and Monocaprin In Situ Hydrogel: Effect on Stability, Mucoadhesion and Texture Analysis and In Vitro Release. Gels, 5, 47 (13p), 2019
  5. Helgadóttir H, Lund SH, Björnsson E, Gizurarson S, Waldum H. Serum concentration and pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Gastroenterology AGA, 156, S308, 2019
  6. Patlolla VGR, Holbrook WP, Gizurarson S, Kristmundsdottir Þ. Evaluation of in vitro mucoadhesiveness and texture profile analysis of doxycycline in situ hydrogels. Pharmazie 74, 9122 (6p), 2019
  7. Helgadóttir H, Ólafsson Í, Andersen K, Gizurarson S. Stability of thromboxane in blood samples. Vascular Health Risk Management, 15, 143-147, 2019
  8. Drobnjak T, Meiri H, Mandala M, Huppertz B, Gizurarson S. Pharmacokinetics of placental protein 13 after intravenous and subcutaneous administration in rabbits. Drug Design Develop. Therapy 12, 1977–1983, 2018
  9. Helgadóttir H , Metz DC , Lund SH , Gizurarson S , Jacobsen EI , Asgeirsdóttir GA , Yngadóttir Y, Björnsson ES. Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial. Journal of Clinical Gastroenterology 51 (6), 486-493, 2017
  10. Hada N, Netzer WJ, Belhassan F, Wennogle LP, Gizurarson S. Nose-to-Brain Transport of Imatinib Mesylate: A Pharmacokinetic Evaluation. (Project supported by Dr. Paul Greengard, Nobel Prize Laureate). Eur J Pharm Sci 102, 46–54, 2017
  11. Drobnjak T, Gizurarson S, Gokina NI, Meiri H, Mandala M, Huppertz B, Osol G. The vasodilatory effect of placental protein 13 (PP13) in pregnant and non-pregnant rat resistance arteries is endothelial-signalled via nitric oxide synthase and cyclooxygenase pathways. Hypertension in Pregnancy 36 (2), 186-195, 2017
  12. Gizurarson S, Helgadóttir EL, Ólafsdóttir S, Ólafsson DR, Sigurðardóttir, Hautala A, Ylihonka K. Heliomycin: Evaluation of its in vivo pharmacokinetics in rats. Int J Res Pharm Biosci 4 (2), 1-6, 2017
  13. Blöndal AB, Almarsdottir AB, Jonsson JS, Gizurarson S. Pharmaceutical care at the primary care clinic in Gardabaer - number and type of drug therapy problems identified among elderly clients. Laeknablaðið 103, 481-486, 2017
  14. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum‑Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine (NEJM), 377 (7), 613-622, 2017
  15. Rolnik D, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Perisco N, Jani JC, Plasencia W, Papaioannou G, Tennebaum Gavish K, Meiri H, Gizurarson S, Nicolaides KH. Aspirin versus placebo in pregnancies at high-risk of preterm pre-eclampsia: a multicentre, double-blind, placebo-controlled trial. Ultrasound Obstetrics Gynecology, 50 (S1), 2, 2017
  16. Nielsen BO, Gunnlaugsson SV, Gizurarson S. Oxandrolone Case Study. Sport Medicine and Rehabilitation Journal 2 (3) 1023 (1-2), 2017
  17. Volmer D, Sokirskaja A, Laaksonen R, Vainio K, Sandler N, Halvorsen KH, Kjome R, Gizurarson S, Muceniece R, Maurina B, Dauksiene J, Ruuben L, Björnsdottir I, Heinämäki J. Medical technology education for pharmacy students and practicing pharmacists in the Nordic and Baltic countries. Pharmacy 4, 29, 2016
  18. Gizurarson S, Meiri H, Huppertz B, Sammar M, Osol G. Placental protein 13 (PP13) shows beneficial effects on the maternal vasculature in pregnant rats: potential benefits in preeclampsia and IUGR. Placenta 35 (9), A85-A85, 2014 (Link)
  19. Sammar M, Huppertz B, Gizurarson S, Meiri H, Osol G. Placental protein 13: Characterization of a naturally occurring variant lacking the carbohydrate recognition domain. Placenta 35 (9), A84-A84, 2014 (Link)
  20. Sammar M, Nisamblatt S, Gonen R, Huppertz B, Gizurarson S, Osol G, Meiri H. The role of the carbohydrate recognition domain of placental protein 13 (PP13) in pregnancy evaluated with recombinant PP13 and the DelT221 PP13 variant. PloS one 9 (7) e102932, 2014 (Link)
  21. Björnsdóttir US, Sigurðardóttir ST, Jonsson JS, Jónsson M, Telg G, Thuresson M, Naya I, Gizurarson S. Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting beta2-agonists in obstructive lung diseases: a population -based, observation study. Int. J Clin Practice 68 (7) 812-819, 2014 (Link)
  22. Lähde A, Guðmundsdóttir SS, Joutsensaari J, Tapper U, Ruusunen J, Ihalainen M, Karhunen T, Torvela T, Jokiniemi J, Järvinen K, Gíslason SR, Briem H, Gizurarson S. In vitro evaluation of pulmonary deposition of airborne volcanic ash. Atmospheric Environment 70, 18-27, 2013 (Link)
  23. Fungfuang W, Nakada T, Nakao N, Terada M, Yokosuka M, Gizurarson S, Hau J, Moon C, Saito TR. Serum leptin concentrations, leptin mRNA expression, and food intake during the estrous cycle in rats. Lab Anim Res 29 (1) 1-6, 2013 (Link)
  24. Gizurarson S, Huppertz B, Osol G, Skarphéðinsson JÓ, Mandalá M, Meiri H. Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents. Fetal diagnosis and therapy 33 (4) 257-264, 2013 (Link)
  25. Sigurðardóttir S, Jónsson JS, Naya I, Telg G, Jónsson M, Thuresson M, Gizurarson S, Björnsdóttir US. Clinical Impacts Of Reimbursement Changes For Fixed Ics/laba Combination Therapy In Well-Controlled Asthma And COPD Patients In Iceland. Am J Respir Crit Care Med. 187, A5225, 2013 (Link)
  26. Almarsdottir AB, Karlsdottir ÁD, Guðmundsson A, Halldórsson M, Gizurarson S. Did the Fall of the Icelandic Banks Affect Psychotropic Drug Use in the Population? Pharmacoepidemiology and Drug Safety 20, S87-S88, 2011
  27. Yokusaka M, Takagi S, Katou M, Pudcharaporn K, Gizurarson S, Ichikawa M, SaitoTR. p-chloroamphetamine-induced rat ejaculation is not associated with the preoptic nucleus or medial nucleus amygdale. Reprod. Med. Biol. 7, 37-43, 2008.
  28. Hrafnkelsdottir K, Valgeirsson J, Bjarnadottir S, Ólafsdottir S, Ólafsdottir K, Héðinsdóttir ST, Magnusdottir EV, Gizurarson S. Immunization prevents DDT build-up in mouse tissues. Int. Immunopharm. 7, 1179-1184, 2007
  29. Freysdottir J, Hardardottir I, Gizurarson S, Vikingsson A. Mucosal tolerance to KLH reduces BSA-induced arthritis in rats – an indication of bystander suppression. J. Clin. Immunol. 27 (3) 284-293, 2007
  30. Gizurarson S, Bechgaard E, Hjortkjær RK. Two intranasal administration techniques give two different pharmacokinetic results. Scand. J. Lab. Animal Sci. 33 (1) 35-38, 2006
  31. Freysdottir J, Hardardottir I, Gizurarson S, Vikingsson A. Mucosal tolerance to KLH reduces BSA-induced arthritis in rats – an indication of bystander suppression. Scand J Rheum 35 (suppl 121), 22, 2006.
  32. Freysdottir J, Bogason ET, Gizurarson S, Vikingsson A. Influence of passive cigarette smoke on joint swelling and on mucosal tolerance induction. Scand J Rheum 35 (suppl 121), 44-45, 2006.
  33. Mayo SL, Tufvesson M, Carlsson HE, Royo F, Gizurarson S, Hau J. RhinoVax ® is an efficient adjuvant in oral immunisation of young chickens and cholera toxin B is an effective oral primer in subcutaneous immunisation with Freund's incomplete adjuvant. In Vivo 19 (2): 375-382, 2005
  34. Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol. Pharm. Bull. 28 (6): 1038-1042, 2005
  35. Freysdottir J, Hardardottir I, Gizurarson S, Vikingsson A Mucosal tolerance to KLH reduces BSA-induced arthritis in rats? an indication of bystander suppression. Immunology 116 (Suppl. 1): 45, 2005
  36. Gissurarson LR, Karlsson GM, Gizurarson S, Hrafnkelsdottir K, Sigurdardottir K, Ofeigsson BG. Improving unbiased left/right training of rats and use of physostigmine to counteract scopolamine-induced short-term memory impairment  Scand. J. Lab. Animal Sci. 31 (2): 101-112, 2004
  37. Lindhardt K, Olafsson DR, Gizurarson S, Bechgaard E. Intranasal bioavailability of diazepam in sheep correlated to rabbit and man. Int. J. Pharm. 231 (1): 67-72, 2002
  38. Gizurarson S: Published referee on work carried out by: Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL; Sniffing neuropeptides a transnasal approach to the human brain. Nature Neuroscience 5: 514-516, 2002
  39. Lindhardt K, Gizurarson S, Stefansson SB, Olafsson DR, Bechgaard E: Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers. Br. J. Clin. Pharmacol. 52 (5): 521-527, 2001
  40. Horvath A, Andersen I, Junker K, Fogh-Schultz BL, Nielsen EH, Gizurarson S, Andersen O, Karman J, Rajjavolgyi E, Erdei A, Svehag SE: Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies. Antiviral Res. 52 (1): 43-53, 2001
  41. Lindhardt K, Ravn C, Gizurarson S and Bechgaard E. Intranasal absorption of buprenorphine – in vivo bioabailability study in sheep. Int. J. Pharm. 205, 159-163, 2000
  42. Olafsson DR and Gizurarson S. Access to the olfactory region. Proceedings Controlled Release of Bioactive Materials. 27: #6318, 2000
  43. S. Gizurarson, F.K. Gudbrandsson, H. Jónsson and E. Bechgaard. Intranasal administration of diazepam – aiming at the treatment of acute seizures. Biol. Pharm. Bull. 22, (4) 1-3, 1999
  44. R.K. Hjortkjær, E. Bechgaard, S. Gizurarson, C. Suzdak and B. Guldhammer. Acute and long term toxicity in the nasal cavity, after administration of benzodiazepines formulated in various glycerols, to rabbits. J. Pharm. Pharmacol. 51, 1-8, 1999
  45. H. Jakobsen, E. Sæland, S. Gizurarson, D. Schulz and I. Jónsdóttir. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infection & Immunity 67, 4128-4133, 1999
  46. S. Gizurarson, M. Sigurdardóttir & B. Stanzeit. Intranasal and subcutaneous administration of diphtheria toxoid. The kinetics of homing to different organs. J.Pharm. Sci .87, 1267-1269, 1998 (link)
  47. S. Gizurarson, H. Aggerbeck, M.R. Gudmundsson and I. Heron. Intranasal vaccination: Pharmaceutical evaluation of the vaccine delivery system and immunokinetic characteristics of the immune response. Pharm. Develop. Techn. 3, 385-394, 1998
  48. S. Gizurarson, H. Aggerbech, F.K. Gudbrandsson, H. Valdemarsson and I. Heron. Intranasal vaccination against diphtheria and tetanus in human subjects. Vaccine Res. 6, 41-47, 1997
  49. S. Gizurarson, T. Thorvaldsson, P. Sigurdsson and E. Gunnarsson. Selective delivery of insulin into the brain. Intraolfactorial absorption. Int. J. Pharm. 147, 135-141, 1997
  50. H. Aggerbeck, S. Gizurarson, J. Wantzin and I. Heron. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15, 307-316, 1997.
  51. E. Bechgaard, S. Gizurarson and R.K. Hjortkjær. Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. J. Pharm. & Pharmacol 49, 747-750, 1997
  52. E. Bechgaard, S. Gizurarson and R.K. Hjortkjær. Solubilization of various benzodiazepines for intranasal administration. Pharm. Develop. Techn. 2, 293-296, 1997
  53. P. Sigurdsson, T. Thorvaldsson and S. Gizurarson. Olfactory absorption of insulin to the brain. Mechanisms of action. Drug Delivery 4, 195-200, 1997
  54. S. Gizurarson, H. Aggerbeck and I. Heron. Intranasal vaccination. Clinical trials in humans. Mucosal Immunol. Updates 4, 33, 1996
  55. E. Bechgaard, S. Gizurarson, R.K. Hjort­kjær & A.R. Sørensen. Intranasal administration of insulin to rabbits using glycofurol as an absorption enhancer Int. J. Pharm. 128, 287-289, 1996
  56. S. Gizurarson, G. Georgsson, H. Aggerbeck, H. Thorarinsdóttir & I. Heron. Evaluation of  local toxicity after repeated intranasal vaccination of guinea pigs. Toxicology 107, 61-68, 1996
  57. S. Gizurarson, H. Aggerbeck, S.G. Árnadóttir, C.H. Mordhorst and I. Heron. Intranasal vaccination against influenza, using pharmaceutical excipients as immunological adjuvants. Vaccine Res. 5, 69-75, 1996
  58. S. Gizurarson, T. Thorvaldsson, P. Sigurdsson and E. Gunnarsson. Selective delivery of insulin into the brain. Intraolfactorial absorption. Int. J. Pharm. 140, 77-83, 1996
  59. S. Gizurarson, V. M. Jónsdóttir & I. Heron. Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics. Vaccine 13, 617-621, 1995
  60. S. Gizurarson, P. Sigurdsson, T. Thorvaldsson & E. Gunnarsson. Technique for administering drugs to the brain and bypassing the blood-brain-barrier. Scand. J. Lab. Anim. Sci. 22, 273-276, 1995
  61. S. Gizurarson, T. Kurata, C. Aizawa & S. Tamura. Pharmaceutical excipients and absorption promoters as additional immunostimulants to a mucosal adjuvant (cholera toxin B subunit). Vaccine Res. 3, 23-29, 1994
  62. S. Gizurarson & H. Thorarinsdottir. Local chemical irritation on mucosal surfaces, measured colorimetrically on the frog palate model. Scand. J. Lab. Anim. Sci. 21, 123-126, 1994
  63. E. Bechgaard, L. Jørgensen, R. Larsen, S. Gizurarson, J. Carstensen & A. Hvass: Insulin and dodecanoyl-L-a-phosphati­dylcholine: in vitro study of the transport through rabbit nasal mucosal tissue. Int. J. Pharm. 89, 147-153, 1993
  64. S. Gizurarson, S. Tamura, C. Aizawa & T. Kurata: Stimulation of the transepi­thel­ial flux of influenza HA vaccine by cholera toxin B subunit. Vaccine 10, 101-106, 1992
  65. E. Bechgaard, S. Gizurarson, L. Jørgensen & R. Larsen: The viability of isolated rabbit nasal mucosa in the ussing chamber and the permeability of insulin across the membrane. Int. J. Pharm. 87, 125-132, 1992
  66. S. Gizurarson, S. Tamura, T. Kurata, K. Hashiguchi & H. Ogawa: The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane. Vaccine 9, 825-832, 1991
  67. S. Gizurarson, S.N. Rasmussen & F. Larsen: Pharmacokinetics of intranasal drug administration. The influence of some biological factors. J. Pharm. Sci. 80, 505-506, 1991 (link)
  68. S. Gizurarson & E. Bechgaard: Insulin-carrying microspher­es. In vitro study. Chem. Pharm. Bull. 39, 1892-1893, 1991
  69. S. Gizurarson & E. Bechgaard: In vitro study of nasal enzyme activity towards insulin. Chem. Pharm. Bull. 39, 2155-2157, 1991
  70. S. Gizurarson, S. Tamura & T. Kurata: Estimating tissue permeability and other bioelectrical parameters using membrane votage and short-circuit current. Chem. Pharm. Bull. 39, 1636-1637, 1991
  71. S. Gizurarson, C. Marriott, G.P. Martin & E. Bechgaard: The influence of insulin and some excipients used in nasal insulin preparations on the mucociliary clearance. Int. J. Pharm. 65, 243-247, 1990 (link)
  72. S. Gizurarson: A simple flow injection method for the determination of blood glucose using Technicon immobilized enzyme coil. J. Autom. Chem. 11, 87-88, 1989 (link)
  73. S. Gizurarson, A. Jensen & S. Foss: A simple flow injection analysis for the studies of drug-protein binding interactions in serum. Acta Pharm. Nord. 1, 291-294, 1989 (link)
  74. S. Gizurarson: Activated carbon for the removal of the ointment base before kinetic assay of nitroglycerin ointment. Fresenius. Z. Anal. Chem. 322, 177-178, 1988 (link)